RDYNYSEPharmaceutical PreparationsFiscal year ends March 31

DR REDDYS LABORATORIES LTD

Financials through fiscal 2026, year ended Mar 31, 2026

$13.08+0.01 (+0.08%)

Close on Oct 19, 2026

DR REDDYS LABORATORIES LTD income statement

AnnualQuarterlyTTM

INR USD

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31	FY 2016 2016-03-31
Revenue	3,802	3,851	3,372	3,062	2,878	2,555	2,463	2,202	2,203	2,101	2,366
Cost of Revenue	1,796	1,598	1,396	1,327	1,350	1,167	1,137	1,008	1,020	932	955
Gross Profit	2,006	2,253	1,976	1,735	1,528	1,388	1,326	1,194	1,184	1,169	1,411
Research & Development	272	324	276	241	235	223	217	223	283	292	273
Selling, General & Admin	1,208	1,110	933	847	833	736	707	697	727	692	699
Operating Expenses	1,434	1,403	1,158	1,024	1,132	1,061	1,100	895	999	968	958
Operating Income	572	850	818	712	396	327	226	299	185	201	453
Interest Expense	42	33	21	18	13	13	14	17	13	12	76
Interest & Investment Income	89	89	69	53	41	35	35	33	45	24	34
Pretax Income	620	908	868	752	434	356	254	321	222	219	415
Income Tax Expense	140	231	196	191	117	124	-21	52	70	39	109
Net Income incl. Noncontrolling Interests	481	677	673	561	316	232	275	269	152	180	306
Minority Interest in Earnings	-4.35	8.29	0	0	–	–	–	–	0	0	0
Net Income	485	669	673	561	–	–	–	–	152	180	306
Net Income to Common	485	669	673	561	316	232	275	269	152	180	306
EPS (Basic)(per share)	0.58	0.80	0.81	0.68	0.38	0.28	0.33	0.32	0.18	0.22	0.36
EPS (Diluted)(per share)	0.58	0.80	0.81	0.67	0.38	0.28	0.33	0.32	0.18	0.22	0.36
Shares Outstanding (Basic, Weighted)(shares)	832	833	832	830	829	829	829	830	829	833	853
Shares Outstanding (Diluted, Weighted)(shares)	833	834	834	832	832	832	830	831	831	835	855
Dividend per Share(per share)	0.09	0.09	0.10	0.37	0.07	0.07	0.06	0.06	0.06	–	–
EBITDA	805	1,052	997	869	554	499	402	473	367	370	610

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 52.8%
Operating margin: 15.0%
Net margin: 12.8%
Return on equity, FY2026: 12.1%

Financial strength

Current ratio: 1.80
Debt to equity: 0.21
Debt to assets: 13.3%
Cash to current liabilities: 9.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.